GTCB Merrimack Pharmaceuticals Announces the Addition of Louis Weiner, M.D., to its Scientific Advisory Board
[Merrimack Pharma continues to “get ready.” They recently hired an experienced manufacturing executive (#msg-10991690), appointed two new directors (#msg-11111367), and inked a downstream processing agreement with Cambrex (#msg-11252196). Phase-2b results in RA are due out any day.]
>> CAMBRIDGE, Mass., July 17 /PRNewswire/ -- Merrimack Pharmaceuticals today announced the addition of Louis Weiner, M.D., to its Scientific Advisory Board (SAB). Dr. Weiner is Chairman of Medical Oncology and Vice President of Translational Research at Fox Chase Cancer Center in Philadelphia, Pennsylvania. A medical oncologist trained in research, Dr. Weiner directed Fox Chase's immunotherapy program and developed and directed the medical oncology fellowship program prior to becoming the department chairman. Dr. Weiner has a longstanding interest and expertise in antibody engineering and antibody-based cancer therapy.
"As we continue to assess the potential products emerging out of the Network Biology Platform, Dr. Weiner's knowledge of oncology both in the clinic and in research will be tremendously beneficial," stated Peter Sorger, Ph.D., Chairman of the SAB of Merrimack. "Dr. Weiner is a leader in his field, and we are eager to gain his insight into our growing pre-clinical and clinical research efforts."
Dr. Weiner joined Fox Chase Cancer Center in 1984. Since 1994 he has been Chairman, Department of Medical Oncology, and has been a Senior Member in the Division of Medical Sciences at Fox Chase Cancer Center since 1995. In 2002 he was named the G. Morris Dorrance Jr. Endowed Chair in Medical Science, and was appointed as Fox Chase's first Vice President for Translational Research. Dr. Weiner received a B.A. with Honors in Biology from the University of Pennsylvania in 1973 and the M.D. from Mount Sinai School of Medicine in 1977.
Dr. Weiner joins SAB members Peter K. Sorger, Ph.D., Professor of Biology and Professor of Biological Engineering, MIT (Chairman of the SAB), Douglas Lauffenburger, Ph.D., Uncas & Helen Whitaker Professor of Bioengineering, MIT, Dan R. Littman, M.D., Ph.D., Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Professor of Pathology and Microbiology, Skirball Institute, NYU, Gavin MacBeath, Ph.D., Assistant Professor, Department of Chemistry and Chemical Biology, Harvard University, James D. Marks, M.D., Ph.D., Professor, Anesthesia and Pharmaceutical Chemistry, Program Member UCSF Comprehensive Cancer Center, UCSF, and Associate Director, Medical-Surgical Intensive Care Unit, San Francisco General Hospital, Barrett Rollins, M.D., Ph.D., Chief Scientific Officer, Dana-Farber Cancer Institute and Associate Professor of Medicine, Harvard Medical School, and Michael Yaffe, M.D., Ph.D., Associate Professor of Biology, MIT.[Whew!]
About Merrimack
Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis or with psoriasis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com. <<
News 
Market Data 
Discover 
AI
